Abstract
Lyme disease is caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne disease in the United States. Disseminated spirochetes can persist in various tissues and can result in a variety of different disease manifestations. Vaccination trials testing various lipoprotein candidates have yielded mixed results despite the generation of robust antibody titers. Data presented in this report demonstrate that a combination vaccine composed of DbpA, BBK32 and OspC is more effective than single or double component formulations and that the ratio of each component dramatically impacts vaccine efficacy when tested in protection experiments against Borrelia following needle inoculation.
Original language | English (US) |
---|---|
Pages (from-to) | 3687-3696 |
Number of pages | 10 |
Journal | Vaccine |
Volume | 23 |
Issue number | 28 |
DOIs | |
State | Published - May 25 2005 |
Keywords
- Borrelia burgdorferi
- Lyme disease
- Prozone
- Vaccine
ASJC Scopus subject areas
- Immunology
- Microbiology
- Virology
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- General Veterinary